We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA blasted generic drugmaker Alvogen for its promotion of the alcoholism treatment disulfiram that omitted potentially life-threatening risks. Read More
Novartis has gained an extra seven months of marketing exclusivity on its blockbuster leukemia drug Gleevec in a settlement with Sun Pharma that permits the Indian manufacturer to launch a generic version of the drug in the U.S. as early as Feb. 1, 2016, the firms said May 15. Read More
The FDA’s proposal to give generic manufacturers the same labelling authority as brand manufacturers is nothing short of “illegal,” argue two prominent FDA observers. Read More
Teva’s zero-hour attempt to prevent generic competition to its blockbuster multiple sclerosis drug Copaxone was halted May 14 when a federal judge threw out its lawsuit calling for ANDA applicants to meet additional requirements. Read More
GlaxoSmithKline’s efforts to expand the indication for its cancer drug Arzerra were dashed when the drug failed to meet its primary endpoint in a Phase III trial. Read More
Proposed copyright requirements in a recent draft of the European Medicines Agency’s clinical trial data transparency policy run counter to EMA’s moves toward greater openness, researchers argue. Read More
The AstraZeneca board of directors on Monday rejected a sweetened, final merger offer from U.S. rival Pfizer, but at least one industry analyst expects wrangling will continue, especially if AZ shareholders step up and demand that the board returns to the negotiating table. Read More
House lawmakers want to give the FDA a $23 million increase in discretionary funds next fiscal year, but would restrict access to certain funds in a bid to prod the agency to finalize guidance on abuse-deterrent properties for opioids. Read More